Page last updated: 2024-11-13
lassomycin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
lassomycin: a ribosomally synthesized peptide that kills Mycobacterium tuberculosis by targeting the ATP-dependent protease ClpC1P1P2; amino acid sequence in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 102602724 |
| MeSH ID | M000602946 |
Synonyms (3)
| Synonym |
|---|
| RS-2025 |
| lassomycin (glrrlfadqlvgrrni) |
| lassomycin |
Research Excerpts
Overview
Lassomycin is a highly basic, ribosomally encoded cyclic peptide. It has an unusual structural fold that only partially resembles that of other lasso peptides.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Lassomycin is a highly basic, ribosomally encoded cyclic peptide with an unusual structural fold that only partially resembles that of other lasso peptides." | ( Lassomycin, a ribosomally synthesized cyclic peptide, kills mycobacterium tuberculosis by targeting the ATP-dependent protease ClpC1P1P2. Akopian, T; Bissell, A; Cao, S; Clardy, J; Epstein, S; Fetterman, A; Gavrish, E; Goldberg, A; Hughes, D; Kandror, O; Lewis, K; Ling, L; Mueller, A; Peoples, A; Sit, CS; Spoering, A; Torrey, H, 2014) | 2.57 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 25.96
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (25.96) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (16.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||